Medical Marijuana – Innovative Pipeline Shows Promise for Treating more than 80 Indications

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData’s Medical Marijuana Thematic Analysis report combines key opinion leader insight, interviews with industry experts and surveys of prescribing physicians and consumers in the US, France, Germany, Italy, Spain, the UK, Canada, Israel and Australia to provide an in-depth review of the medical marijuana market. The medical marijuana market is expected to grow at a CAGR of 81.3% between 2018 and 2025. Growth in the medical marijuana market will be driven by the approval of marketed drugs in additional markets. For example, Epidiolex is approved in the US and recently launched in France, Germany and the UK. The drug, which is used to treat refractory childhood-onset epilepsies is expected to launch in Spain and Italy, among other markets in 2020. Similarly, GW Pharma's Sativex is approved for muscle spasticity in patients with multiple sclerosis in many European markets and is at the pre-registration stage in the US. Launching in this market will drive sales. Furthermore, label expansion opportunities and the launch of novel agents in the coming years will lead to explosive growth making the market value worth an estimated $3.2B by 2025.
The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena.
Key Questions Answered in This Report
What was the value of the medical marijuana market in 2018?
What challenges do biopharmaceutical companies developing medical marijuana therapeutics face that are unique to this field?
Which patients do prescribing physicians think are most likely to benefit from treatment with medical marijuana?
What are the concerns and perceptions of prescribers and potential consumers of medical marijuana across the nine markets covered in this report?
What are the unmet needs in the medical marijuana market and what opportunities remain for industry players?

Scope

Overview of the potential applications of medical marijuana including SWOT analysis of marketed and late-stage pipeline agents

In-depth analysis of diseases where at least one medical marijuana product is used in clinical practice

Key topics covered include assessment of strategic consolidations, unmet needs, clinical trial mapping, examination of market opportunities and challenges

Discussion of late-stage pipeline products including a sales forecast from 2018-2025

Pipeline analysis: comprehensive data and discussion of emerging trends, the significance of the endocannabinoid system in various conditions, the route of administration of pipeline agents and the markets in which the drugs are expected to launch.

Analysis of the current and future market competition in the global medical marijuana therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The medical marijuana market is expected to grow at a CAGR of 81.3% from 2018 to 2025. The launch of pipeline agents Zygel and lenabasum will add to the number of products in the market which will reaching a global value of $3.2 billion in 2025.

There are currently five approved medical marijuana therapies across the countries discussed in this report (US, France, Germany, Italy, Spain, UK, Canada, Israel and Australia). The products are Epidiolex, Marinol, Sativex, Nabilone and Syndros. The main issues presented are the fact that Epidiolex and Sativex are unaffordable without coverage from health insurance policies. The THC-content of products like Marinol also presents a barrier to approval in markets other than the US. This is because of its psychoactive properties. Another clinical obstacle is the tolerability of oromucosal sprays as pediatric patients can have difficulty with the taste of these therapies.

Other unmet needs include updating treatment guidelines and conducting more clinical research into the safety and efficacy of medical marijuana products for chronic diseases.

KOLs were impressed by the diversity of the medical marijuana pipeline and emphasized the need for more research as an urgent unmet need.

There is widespread diversity in the size and geographical location of companies investigating medical marijuana. Additionally, an active deals landscape between non-profit research organizations, academic institutions and biopharmaceutical companies presents opportunities for more comprehensive studies in the field.

Refining dosing arrangements and gaining marketing authorization in various markets is expected to be a challenge that will persist in the market as well as the enforcement of good manufacturing practices that meet the standards set by different regulatory bodies such as the FDA, the Therapeutic Goods Administration (TGA) in Australia and the European Medicines Agency (EMA).

Rapid uptake of therapeutics is anticipated due to the refractory nature the conditions for which products are being developed. Patients with Dravet syndrome and Lennox-Gastaut syndrome are likely to have hundreds of seizures every two weeks which causes significant disruption to the quality of life of patients and their carers.

High costs of therapy associated with products treating orphan indications are expected to remain an unmet need in the foreseeable future.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global medical marijuana market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global medical marijuana market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Albany Molecular Research
Almirall
Axim Biotechnologies
Bionorica
Cannabis Science
Ci Therapeutics
Corbus Pharma
Eli Lilly
Emerald Bioscience
Emerald Health Sciences
GW Pharma
Insys Therapeutics
Ipsen
LTS Lohmann Therapie-Systeme
Neopharm
Novaliq
One World Cannabis
Panaxia
RespireRx
STERO Biotechs
SUDA Pharma
Tetra-Bio Pharma
Teva
Therapix Biosciences
Unimed Pharma
Veritas
Yom Chai
Zynerba Pharma

Table of Contents

Table of Contents

1. Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL Insights

3. Introduction to Medical Marijuana

3.1 Defining Medical Marijuana

3.2 Overview of Cannabinoids

3.3 Overview of Cannabinoid Receptors

3.4 The Endocannabinoid System

4. Medical Marijuana: The Global Picture

4.1 The History of Medical Marijuana

4.2 Medical Marijuana in the US

4.3 Medical Marijuana in France

4.4 Medical Marijuana in Germany

4.5 Medical Marijuana in Italy

4.6 Medical Marijuana in Spain

4.7 Medical Marijuana in the UK

4.8 Medical Marijuana in Canada

4.9 Medical Marijuana in Israel

4.10 Medical Marijuana in Australia

4.11 Medical Marijuana in the Media

5. Marketed Products

5.1 Marketed Products by Indication

5.2 Marketed Product Profiles

5.3 Dosing

5.4 SWOT Analysis of Marketed Products

6. Pipeline Assessment

6.1 Overview of Late-Stage Pipeline Products

6.2 Late-Stage Pipeline Products by Indication

6.3 Phase II Pipeline Products

6.4 Phase III Pipeline Products

6.5 SWOT Analysis of Pipeline Products

7. Clinical Trials

7.1 Overview of Marijuana Products in Clinical Development

7.2 Ongoing Clinical Trials

7.3 Innovative Early-Stage Approaches

7.4 Leading Industry Sponsors

8. R&D Strategies

8.1 Receiving Permission to Conduct Clinical Trials

8.2 Companies in the Late-Stage Pipeline

8.3 Clinical Trial Design

8.4 Pipeline by Route of Administration

9. Early-Stage Pipeline Products

9.1 Indications in the Early-Stage Pipeline

10. Focus Indication: Anorexia Nervosa

10.1 Introduction to Anorexia Nervosa

10.2 Complications of Anorexia

10.3 Treatment Strategies

10.4 The Endocannabinoid System in Anorexia

10.5 Medical Marijuana Products for Anorexia

11. Focus Indication: Muscle Spasticity

11.1 Introduction to Muscle Spasticity

11.2 Muscle Types

11.3 Muscle Contraction

11.4 Etiology of Muscle Spasticity

11.5 Treatment Algorithm for Muscle Spasticity

11.6 Medical Marijuana Products for Muscle Spasticity

12. Focus Indication: Pain

12.1 Introduction to Pain

12.2 Types of Pain

12.3 Neuropathic Pain

12.4 Cancer Pain

12.5 Medical Marijuana Products for Pain

13. Focus Indication: Epilepsy

13.1 Introduction to Epilepsy

13.2 The Pathophysiology of Seizures

13.3 Types of Seizures

13.4 Childhood-Onset Epilepsies

13.5 Medical Marijuana Products for Epilepsy

14. Case Study: Charlotte’s Web

14.1 The Story of Charlotte Figi

14.2 KOL Perspectives

15. Industry Insights

15.1 Considerations of Stakeholders

16. Deals Landscape

16.1 Strategic Consolidations

16.2 Mergers and Acquisitions

17. Pricing and Reimbursement Strategy

17.1 Pricing and Reimbursement in the US

17.2 Pricing and Reimbursement in the EU and France

17.3 Drug Prices in Germany

17.4 Drug Prices in Italy

17.5 Pricing in Spain, the UK and Australia

17.6 Pricing in Canada and Israel

17.7 KOL Perspectives

18. Unmet Needs

18.1 Overview of Unmet Needs

18.2 KOL Perspectives

19. Market Challenges and Opportunities

19.1 Challenges for Medical Marijuana Pharmacotherapy

19.2 Opportunities for Medical Marijuana Pharmacotherapy

20. Prescriber Perspectives

20.1 Take-Home Messages from the Prescriber Survey

20.2 Key Messages from US Prescribers

20.3 Key Messages from 5EU Prescribers

20.4 Key Messages from Canadian Prescribers

20.5 Key Messages from Israeli Prescribers

20.6 Key Messages from Australian Prescribers

21. Consumer Perspectives

21.1 Take-Home Messages from the Consumer Survey

21.2 Consumer Perspectives in North America

21.3 Consumer Perspectives in the 5EU

21.4 Consumer Perspectives in Israel

21.5 Consumer Perspectives in Australia

22. Market Outlook

22.1 The Future of Medical Marijuana

22.2 Market Drivers

22.3 Market Barriers

22.4 Market Potential

22.5 Take-Home Messages

22.6 Closing Statements from Industry Experts and KOLs

23. Appendix

23.1 Sources

23.2 Study Design

23.3 Methodology

23.4 Primary Research

23.5 About the Authors

23.6 About GlobalData

23.7 Contact Us

Frequently asked questions

Medical Marijuana – Innovative Pipeline Shows Promise for Treating more than 80 Indications thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Medical Marijuana – Innovative Pipeline Shows Promise for Treating more than 80 Indications was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Medical Marijuana – Innovative Pipeline Shows Promise for Treating more than 80 Indications in real time.

  • Access a live Medical Marijuana – Innovative Pipeline Shows Promise for Treating more than 80 Indications dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.